Lv81
8450 积分 2020-10-11 加入
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
1小时前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
1小时前
已完结
Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use
1小时前
已完结
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer
6天前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
29天前
已完结
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
2个月前
已完结
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
2个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
2个月前
已关闭
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
3个月前
已完结
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
3个月前
已完结
皖公网安备34019202002308
